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Abstract Vascular endothelial growth factor (VEGF) inhibitor
medications such as ranibizumab, pegaptanib and bevacizumab
are in use for the treatment of neovascular age-related macular
degeneration (AMD) and other retinal conditions, although only
ranibizumab and pegaptanib are approved for these conditions.
In contrast, bevacizumab was developed for the intravenous
systemic treatment of colorectal cancer and is not formulated
for intravitreal use, but is commonly used off-label in ophthal-
mology. European Union legislation permits the use of drugs
outside the terms of their licence (‘off-label’) only under certain
circumstances, such as during clinical trials, compassionate/
named patient use in the absence of a licensed alternative,
emergency scenarios (e.g., pandemics) or at the discretion of a
treating physician. In such cases, patients should be fully in-
formed regarding their treatment and any potential risks in-
volved. Off-label drug use can be an important tool to provide
patients with treatment in cases of unmet medical need. How-
ever, the use of an unlicensedmedicinal product, when a suitable
licensed alternative is available, puts prescribing physicians at
risk of liability if safety issues arise. Emerging clinical evidence
suggests safety differences exist between ranibizumab and
bevacizumab.
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Introduction
Age-related macular degeneration (AMD) is the leading cause
of legal blindness in the elderly [1–3]. Vascular endothelial
growth factor A (VEGF-A) plays an important role in vascular
homeostasis, promotion of endothelial cell proliferation and
the growth of new blood vessels [4, 5]. However, expression
of VEGF-A in the retina is a major mediator of angiogenesis
and vascular leakage in neovascular AMD, which, if left
untreated, can result in loss of central vision [6].
Intravitreal injection of a VEGF-A inhibitor is currently the
primary treatment for neovascular AMD.At present, four anti-
VEGF therapies are used for such patients: pegaptanib (Macu-
gen®, Pfizer, New York City, NY, USA), alfibercept (Eylea®,
Bayer HealthCare, Berlin, Germany/Regeneron Pharmaceut-
icals, Inc., Tarrytown, NY, USA), ranibizumab (Lucentis®,
Novartis, Basel, Switzerland/Genentech, South San Fran-
cisco, CA, USA/Roche, Basel, Switzerland) and bevacizumab
(Avastin®, Genentech/Roche). Pegaptanib, a ribonucleic acid
aptamer that only blocks the pathologic VEGF-A 165 iso-
form, was the first anti-VEGF therapy to be approved for
intravitreal treatment [7], although it is in limited use, as
pan-VEGF-A blockers produce better outcomes [8]. Afliber-
cept is a fusion protein originally developed for oncology use
that binds all forms of VEGF-A, as well as VEGF-B and
placental growth factor (PIGF), additional angiogenic growth
factors that appear to play a role in tumor angiogenesis and
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inflammation [9, 10]. Ranibizumab is a recombinant, affinity-
matured, humanised antibody fragment (Fab) against VEGF-A
produced in an E. coli expression system [6]. Ranibizumab was
designed specifically for intravitreal use, and, in addition to
AMD, is approved for the treatment of diabetic macular oede-
ma in the European Union (EU) and macular oedema second-
ary to retinal vein occlusion in the EU and the USA [6, 11, 12].
Bevacizumab is a full-length, recombinant, humanised anti-
body to VEGF-A produced in a Chinese hamster ovary mam-
malian expression system [5]. As such, bevacizumab (unlike
ranibizumab) is glycosylated, which prolongs systemic half-
life, and contains the fragment crystallisable region (Fc region)
of the antibody, which facilitates systemic absorption [13].
Bevacizumab was designed to have a long systemic half-life,
important for use in oncology, and is not approved for intra-
vitreal use [5]. Despite this, bevacizumab is often used, off-
label and unlicensed, for intravitreal treatment by ophthalmol-
ogists. This practice began and spread rapidly in the period
following release of the key clinical trial results of ranibizumab
but prior to its approval, when ranibizumab was not yet avail-
able. Given the huge unmet medical need and rapid loss of
vision in patients with AMD, there was little other choice
during that time in many health economies but to use off-
label bevacizumab. Thus, bevacizumab use in ophthalmology
grew rapidly and has remained widespread in several econo-
mies. Currently, there is a perception that bevacizumab and
ranibizumab are identical in terms of safety and efficacy. As
single vials of bevacizumab intended for intravenous use can be
compounded into many small doses for intraocular use, there is
also a cost difference between the two drugs that some may
argue takes precedence over inequalities in the safety and
efficacy between the drugs [14]. However, the process of com-
pounding results in the creation of an unlicensed medicine [15].
Several head-to-head trials of ranibizumab and bevacizu-
mab are ongoing (Table 1). The 12- and 24- month of the
Comparison of AMD Treatment Trials (CATT) study were
reported in April 2011 and April 2012, respectively [16, 17].
The Inhibition of VEGF in Age-related choroidal
Neovascularisation (IVAN) study released 12-month results
in May 2012 [18]. For this reason, we consider it timely to
evaluate the safety profiles of ranibizumab and bevacizumab,
examine the need for continuing pharmacovigilance to ensure
that rare adverse events (AEs) are detected for both drugs, and
consider the risks, for both patients and clinicians, associated
with unlicensed prescribing. A debate-style symposium at the
2nd World Congress on Controversies in Ophthalmology in
Barcelona, Spain, in March 2011, centred around a discussion
of these topics, and is the basis of this review.
Patient safety and the importance of post-marketing
surveillance
While serious failures in patient safety are uncommon,
patient safety incidents or adverse health care events are a
global concern. Many such incidents are preventable—for
example, around 15 % of hospital-acquired infections are
thought to be avoidable [19]. Fatal adverse drug reactions
are thought to be the sixth leading cause of death in the US
[20]. Over 20,000 people/year in the UK are reported to
have experienced serious adverse reactions to drugs [21],
and this may be just a small proportion of the true figure. In
UK National Health Service hospitals, patient safety inci-
dents are estimated to occur in around 10 % of admissions,
and only a fraction are reported [22]. A review of patient
safety incident reports submitted to the National Patient
Safety Agency from across England and Wales relating to
anti-VEGF use in ophthalmic care found 166 relevant
reports from 2003 to June 2010, suggesting considerable
under-reporting of such incidents [23]. The incidents so
reported included infection and inflammation, delays in
treatment, problems with medication availability, errors in
medication, and errors in the patient or eye injected [23]. It
is recognised that under-reporting of adverse drug reactions
is significant [24].
With licensed medications, reports from post-marketing
surveillance and pharmacovigilance programmes add to data
from clinical trials to build a picture of the safety profile of a
drug in a given indication and patient population. Since seri-
ous safety signals may not be detected during clinical trials
and may only appear during post-approval marketing [25].
collection of safety data from post-marketing studies and
routine clinical use is critical. One such example is rosiglita-
zone (Avandia®, GlaxoSmithKline, London, UK), approved
for treatment of type 2 diabetes mellitus in 2000. In 2007, a
black-box warning on myocardial ischaemia was added to the
label owing to concerns that had arisen in independent meta-
analyses of 42 short-term randomised controlled trials involv-
ing 27,847 patients, linking rosiglitazone with increased risks
of myocardial infarction and death from cardiovascular causes
[26–28]. Subsequently, a number of observational studies
Table 1 Current head-to-head trials of ranibizumab versus bevacizu-
mab in neovascular age-related macular degeneration
Study Country N (target) Trial identifier
CATT [14] US 1208 NCT00593450a
IVAN UK 600 ISRCTN92166560b
GEFAL France 600 NCT01170767a
VIBERA Germany 366 NCT00559715a
LUCAS Norway 420 NCT01127360a
BRAMD Netherlands 320 NTR1704c
MANTA Austria 320 NCT00710229a
a ClinicalTrials.gov; b International Standard Randomised Controlled
Trial Number Register; c Nederlands Trial Register
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using routine clinical data (Medicare claims data) for rosigli-
tazone and pioglitazone, a member of the same drug class,
found a significantly increased risk of arterial thromboembolic
events (ATEs) with rosiglitazone versus pioglitazone [29–31],
and rosiglitazone use was suspended in Europe in 2010.
Importantly, the initial clinical trials of rosiglitazone were
not designed to generate cardiovascular safety outcomes data,
and this AE was not detected [24]. This case demonstrates the
importance of rigorous post-marketing surveillance to enable
detection of serious safety signals that may not be apparent
pre-registration. However, pharmaceutical companies do not
typically enter into official pharmacovigilance programmes
for indications that are unlicensed or off-label, as such use is
at the discretion of the prescriber. In addition, if a patient dies,
or misses an appointment due to disability resulting from a
stroke, the ophthalmologist often does not learn of these
events, which then go unreported irrespective of whether a
formal pharmacovigilance programme is in place. This illus-
trates the importance of large-scale clinical trials such as
CATT, even for off-label drugs, to assess safety in a more
robust manner.
Role of the regulatory system in protecting patients
and physicians
The key principal underpinning the regulations governing the
production, distribution, and use of medicines is the safe-
guarding of public health. For this reason, EU legislation
requires a Marketing Authorisation (MA) to be granted for
the purposes of placing a medicinal product on the market
[32, 33]. The medicines regulatory system in the UK was
developed following the thalidomide tragedy, and exists to
protect the public from exposure to unsafe drugs [34]. AnMA
is granted if the applicant can demonstrate that the drug is safe,
efficacious, and of suitable quality. Medicines must not be
promoted without, or outside the terms of, their MA. Further-
more, theMA provides a clear and comprehensive description
(via the Summary of Product Characteristics, SmPC) of how a
medicine may be used. If a drug is prescribed in a manner
outside the description given in the SmPC (or ‘label’), then
this use is known as off-label (used in an indication, dosage or
patient group not specified in the label), unlicensed (modified
in form or strength in a way that has not been assessed or
approved, such as splitting a vial into syringes) or potentially
both off-label and unlicensed. The use of bevacizumab to treat
AMD is an example of the latter, since both the indication and
the formulation are currently unapproved.
EU regulations envisage off-label/unlicensed use only un-
der limited ‘special need’ circumstances, including authorised
clinical trials, compassionate/named patient use when no other
treatment is available, emergency scenarios (e.g., pandemics)
or at the discretion of a treating physician [32, 33, 35]. Where
doctors choose to prescribe under one of the exemptions
above, patients must be fully informed, in accordance with
their fundamental right to be informed about the treatments
they receive, about the presence of any approved alternative
treatments, and be able to participate in treatment decisions
[36]. The concept of informed consent for off-label/unlicensed
use is reflected in the European Convention of Human Rights
and associated case law, as well as in national laws and ethical
guidance [37]. National requirements for informed consent
vary across the EU, but it is generally agreed that physicians
should inform their patients of the unlicensed nature of the
proposed treatment, the reasons for proposing the treatment,
any potential side-effects, the risks and benefits, and available
alternatives [37–42]. For example, in the UK, General Med-
ical Council (GMC) guidance on prescribing off-label/unli-
censed medicines states that:
[Y]ou must explain the reasons for prescribing a med-
icine that is unlicensed or being used outside the scope
of its licence where there is little research or other
evidence of current practice to support its use, or the
use of the medicine is innovative [43, 44].
While the use of a drug outside the terms of its licence
can be an important tool to provide patients with treatment
in cases of unmet medical need where there are no licensed
therapy options, the use of an unlicensed medicinal product,
when a suitable tested and approved alternative is available,
may put prescribing physicians at risk of liability if safety
issues arise. Should any untoward event arise through the
use of that drug, the treating physician would have the
burden of proof to demonstrate that its use was performed
as standard of care [45]. By prescribing licensed drugs,
physicians can be confident that the risk–benefit balance
of the therapy has been assessed and is supported by quality
pre-clinical and clinical data. Physicians should also bear in
mind that cost is not a relevant consideration when deciding
whether to prescribe a drug off-label. In the UK, GMC
guidance does not allow doctors to factor in the cost of a
medicine [43, 44]. Rather, doctors must be satisfied that an
unlicensed or off-label medication would better serve the
patient’s needs than an appropriately licensed alternative,
and be satisfied that there is a sufficient evidence base and/
or experience of using the medicine to demonstrate its safety
and efficacy. In March 2012, the Court of Justice of the
European Union ruled that a Polish law allowing the import
and sale of unapproved and less costly medications to sim-
ilar, approved drugs under the ‘special need’ exemption
breaches EU law [46]. The ruling noted that the exemption
must be used only when completely essential and based solely
on therapeutic need. If approved medicines with the same
active ingredients, dosages, and forms are on the market, there
cannot be a requirement for ‘special needs’, and financial
considerations cannot be used as a justification.
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Safety of anti-VEGF therapies in the treatment
of neovascular AMD
As a result of the important role of VEGF in promoting
vascular homeostasis, there is a theoretical risk of ATEs
following the use of any VEGF inhibitor [4, 47, 48]. When
anti-VEGF agents are given systemically, there is a known
risk of increased blood pressure and ischaemic cardiac
events. This is noted in the black-box label of bevacizumab.
This is important, since studies have shown increased risks
of stroke and coronary heart disease in untreated patients
with AMD compared with controls [49–51]. A difference in
the rates of these events in patients with AMD treated with
ranibizumab and bevacizumab would be of particular clini-
cal relevance.
As bevacizumab and ranibizumab are derived from the
same mouse monoclonal anti-VEGF antibody, they are
sometimes perceived to have equivalent safety and efficacy
[14]. However, as reviewed recently [52], bevacizumab and
ranibizumab are different at the molecular level, so safety
and efficacy data cannot be extrapolated. While bevacizu-
mab is a full-length recombinant antibody, ranibizumab was
developed by inserting sequences from the parent antibody
into a human antigen binding fragment (Fab) framework.
The humanised Fab was then selectively mutated by chang-
ing six amino acids to increase its affinity for binding and
inhibiting VEGF-A over the original mouse antibody and
bevacizumab [6]. As an antibody fragment, ranibizumab has
a relatively short systemic elimination half-life, estimated at
~2 hours compared with ~20 days for bevacizumab, and
lacks the Fc region of an antibody (present in bevacizumab),
which has been reported to initiate complement activation
and an immune response [53, 54]. In addition, bevacizumab
reaches the systemic circulation following intravitreal injec-
tion more rapidly than might be expected for a full-length
antibody. Experiments in rabbits demonstrated the vitreous
half-life of intravitreal bevacizumab to be 4.3 days, similar
to that of the much smaller molecule of ranibizumab
(2.8 days) [55, 56]. An explanation for this has been pro-
vided by studies in mice indicating that the neonatal Fc
receptor, expressed by retinal pigment epithelial cells, is
involved in the active transport of bevacizumab across the
blood–retina barrier [13]. This receptor may be upregulated
in eyes with neovascular AMD, leading to rapid elimination of
bevacizumab from the vitreous humor into the systemic cir-
culation [13]. In comparison, a study of the half-life in humans
measured intraocular concentrations of bevacizumab from 29
patients, and found the half-life of bevacizumab to be dose-
dependent. The half-life of bevacizumab from a single 1.5 mg
dose was determined as 7.85 days, compared with 11.67 days
for a 3.0 mg dose [57]. Studies in rabbits detected bevacizu-
mab, but not ranibizumab, in the serum following intravitreal
injection, suggesting that bevacizumab may be more likely to
have clinically observable systemic effects than ranibizumab
[55, 56]. Importantly, systemic VEGF inhibition has been
demonstrated in patients with diabetic retinopathy following
intravitreal bevacizumab injection [58]. Plasma VEGF levels
were significantly reduced for at least 30 days (p<0.001) after
a single bevacizumab injection [58]. Similarly, patients with
AMD treated with intravitreal bevacizumab have a significant
reduction in plasma VEGF levels up to 28 days after injection
(p<0.001), but no significant reduction in plasma VEGF
following ranibizumab treatment [59].
The molecular and pharmacological differences between
ranibizumab and bevacizumab signal that safety and effica-
cy data from one cannot be extrapolated to the other. An
accumulating body of clinical and regulatory evidence sup-
ports the hypothesis that these fundamental differences
translate into clinical differences in the safety profile of
these two drugs.
A recent, non-randomised, comparative study in patients
with AMD confirmed bevacizumab as an independent and
significant predictor for new ATEs, associated with around a
10-fold higher risk than ranibizumab [60]. Two independent
retrospective analyses of the US Medicare claims database
also report differences in rates of systemic AEs with ranibi-
zumab and bevacizumab [61, 62]. The first examined data
from 146,942 patients with AMD, to compare the risks of
several systemic AEs with current treatments for AMD.
While the primary analysis of this study did not identify
significant differences in risk between the ranibizumab and
bevacizumab groups, a secondary analysis in which the
study population was limited to 40,841 newly-treated patients
who received bevacizumab or ranibizumab only showed sig-
nificantly increased risks of all-cause mortality and stroke
with bevacizumab (Fig. 1) [61]. These results are consistent
with those of a second (unpublished) Medicare data analysis,
which showed a significantly increased risk of mortality with
bevacizumab versus ranibizumab in an analysis of 77,886
claimants [62]. While the limitations of such database analy-
ses are recognised, neither showed fewer systemic ATEs with
bevacizumab, indicating that there may be an emerging safety
signal, as was the case with the early warning signs with
rosiglitazone discussed above.
Several prospective comparative studies of ranibizumab
and bevacizumab are ongoing. None have the statistical power
to determine if a safety difference exists between the drugs.
Considering the CATT study primary efficacy endpoints at
12 months, monthly injections of bevacizumab successfully
demonstrated non-inferiority to monthly ranibizumab as well
as ranibizumab given as needed [16]. It is important to note
that in Year 1 there were no differences in venous thrombolic
events or ATEs; however, there was a significantly higher rate
of serious systemic AEs (of which 80.5%were associatedwith
hospitalisation) with bevacizumab compared with ranibizu-
mab, which remained significantly higher after adjustment
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for baseline demographics and coexisting illnesses (p00.04)
[14]. In CATT Year 2, ranibizumab maintained visual acuity
gains from Year 1 with both regimens [17]. Greater numerical
visual acuity gains and significantly fewer injections were seen
with ranibizumab versus bevacizumab as needed, and the 2-
year CATT data confirmed an overall significantly higher risk
of serious systemic adverse events with bevacizumab versus
ranibizumab (p00.004) [17]. ATEs, systemic haemorrhage,
congestive heart failure, venous thrombotic events, hyperten-
sion, and vascular death were more frequent in bevacizumab-
treated patients, and as in Year 1, there were significantly more
gastrointestinal disorders in patients treated with bevacizumab
compared with ranibizumab (p00.005) [17].
Similarly to CATT, the 2-year IVAN study includes com-
parisons between ranibizumab and bevacizumab and be-
tween regimens [18]. However, there is no comparison
between individual treatment arms, due to the study lacking
the statistical power to compare these groups. The primary
endpoint of the study was corrected visual acuity after
2 years. The Year 1interim analysis showed that improve-
ment in visual acuity was greater in the ranibizumab arms
than in the bevacizumab arms [18]. Bevacizumab failed to
demonstrate non-inferior vision gains to ranibizumab at
1 year using a 3.5 letter non-inferiority margin (95 % CI,
−4.04, 0.06; p00.056) [18]. Secondary findings (e.g., fluid
on optical coherence tomography, dye leakage on angio-
gram) also favoured ranibizumab [18]. There was no signif-
icant difference in the proportion of patients experiencing at
least one serious adverse event (SAE) with ranibizumab
versus bevacizumab in IVAN at 1 year [18]. However, there
were numerically more SAEs with bevacizumab (n037)
than with ranibizumab (n030) [18].
Given the relatively small study populations in CATT,
IVAN, and the other current head-to-head trials, it is unlike-
ly that any of these studies are powered to reveal significant
differences in rates of individual serious AEs between treat-
ment groups [63]. There is the possibility that a meta-
analysis of these trials may reveal a safety signal, and there
remains a huge need for large studies powered for safety to
elucidate fully the incidence of infrequent serious AEs.
In addition to the fundamental structural and pharmacoki-
netic differences between the two drugs, manufacturing and
packaging specifications also differ between ranibizumab and
bevacizumab. Ranibizumab is manufactured to meet United
States Pharmacopeia (USP) standards for ophthalmic solu-
tions (USP789), which are more stringent with regard to
sterility and particulate matter than the requirements for intra-
venous medications such as bevacizumab (USP788) [64]. In
the latter, more particulate matter is tolerated [65], which has
the potential to cause irritation and inflammation if injected
into the eye. Once manufactured, ranibizumab is packaged
into sterile, single-use vials. In contrast, bevacizumab vials are
intended for single use as an intravenous infusion, and in
practice undergo compounding into smaller aliquots for use
in AMD care [66]. Active immunoglobulin levels in com-
pounded bevacizumab samples have been shown to vary
significantly between compounding pharmacies, leading to
the possibility of variable efficacy depending on the amount
of antibody present [67]. In addition, compounded bevacizu-
mab samples have also been shown to have an increase in
particulate matter, which may lead to elevated intraocular
pressure and inflammation [67].
The recent analysis of Medicare claims data reported that
patients given bevacizumab were significantly more likely to
require treatment for ocular inflammation than those receiving
ranibizumab [62], and a precautionary recall of compounded
bevacizumab was issued in March 2012 by a leading National
Health Service (NHS) hospital compounding pharmacy in the
UK after a number of reports of suspected sterile endophthal-
mitis following intravitreal injection [68]. Whenever the phy-
sician does not control the source of drugs, there is an
increased potential for human error, either by an incorrect
dose or incorrect drug [69]. A recent series of endophthalmitis
cases in China was traced back to counterfeit bevacizumab
being used by the compounding pharmacy [70]. Finally, there
is an increased risk of contamination when single-use vials are
accessed multiple times. Clusters of cases of endophthalmitis
traced back to such contamination led to an alert being issued
by the US Food and Drug Administration [71]. More recently,
the Medical Products Agency in Sweden issued a position












Fig. 1 Hazard ratios adjusted
for patient characteristics (with
95 % confidence intervals) for
systemic adverse events at
1 year in the secondary analysis
of a Medicare claims database
study (n040,841) [61]
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statement in March 2012 recommending the use of ranibizu-
mab for retinal conditions, due to concerns that available
safety data for bevacizumab in this setting are inadequate,
but indicate an increased risk for ocular inflammation and
potentially also for certain systemic adverse events [72]. In
February 2012, the Emilia–Romagna region of Italy tempo-
rarily suspended the off-label use of bevacizumab for newly
diagnosed patients following a response from the Italian Med-
icines Agency (AIFA) to a request from Emilia–Romagna to
reimburse bevacizumab through a law that regulates the off-
label use of drugs at national level [73]. AIFA stated that the
results of the CATT study do not justify the off-label use of
bevacizumab, both in terms of safety and efficacy [73]. In
contrast, having previously supported and endorsed use of
bevacizumab in patients [74], in 2012 the German Ophthal-
mological Society, the Retinological Society, and the Associ-
ation of Ophthalmologists in Germany released a new
statement on therapeutic strategies for treating wet AMD in
response to the CATT study report, which refers to a similar
efficacy of bevacizumab but also acknowledged the legal
implications of off-label use [75]. In December 2011 the
Royal College of Ophthalmologists stated that the College
believes the use of ranibizumab for AMD should be the
default position until the NHS commissions a National Insti-
tute for Health and Clinical Excellence (NICE)/ Medicines
and Healthcare products Regulatory Agency (MHRA) assess-
ment of bevacizumab and until a national policy is formulated
[76]. To date, no such new national policy in the UK has been
developed.
Discussion
Debate currently surrounds the use of unlicensed treatments
in medicine, with wide-reaching implications for informed
consent, patient safety, and the regulatory process itself. It is
our hope that greater understanding of these issues by oph-
thalmologists may lead to better patient care in ophthalmic
practice.
The primary role of regulatory systems is to promote
patient safety. Despite this, the regulatory apparatus sur-
rounding post-marketing monitoring and safety is less co-
herent than that concerned with the drug discovery,
development and MA process. Only in recent years, follow-
ing public and media interest in high-profile drug safety
cases such as those of rosiglitazone and rofecoxib (Vioxx®,
Merck, Whitehouse Station, NJ, USA), is the process of
proving drug safety receiving similar attention to the process
of demonstrating efficacy, and this has led to reform of EU
pharmacovigilance laws. However, in order to make real
differences in patient safety, regulatory bodies must make
rational safety decisions and allocate resources to implement
changes. Policy decisions must be made considering all
available evidence. In particular, patient safety must take
precedence over economic considerations. Professional bod-
ies could have an important role in raising safety concerns in
ophthalmology in general and with regulatory authorities.
For example, the Royal College of Ophthalmologists has
provided detailed guidance on patient safety in ophthalmol-
ogy, which should be of merit to eye-care teams to improve
patient safety in local departments and aims to keep mem-
bers updated of emerging issues [72, 77].
Ranibizumab and bevacizumab are distinctly different at
the molecular level, have different target profiles and differ-
ent approved routes of application. These differences mean
that safety and/or efficacy data from one cannot be extrap-
olated to the other, and the rosiglitazone case provides a
timely illustration that agents in the same drug class can
have significant differences in safety profiles. Since bevaci-
zumab is unlicensed for use in ophthalmology, post-
marketing pharmacovigilance normally implemented for li-
censed drugs has not been carried out to date. Existing
clinical evidence comes solely from clinical studies, with a
number of studies reporting trends towards an increased risk
of systemic AEs with bevacizumab [16–18, 57–59]. Though
such studies have limitations, the consistency of findings
reinforces the plausibility of patient safety differences be-
tween these VEGF inhibitor agents. However, large studies
specifically powered for safety are needed to reveal the
significance of rare serious AEs with these agents. The
issues discussed here regarding pharmacovigilance and un-
professional compounding of bevacizumab could be
addressed by professional organizational bodies introducing
guidelines in these matters.
Physicians may be liable for serious AEs that occur in
patients they treat, particularly if they have not provided
patients with sufficient information about the unlicensed
drug to allow them to provide informed consent. This leads
to particular concerns for ophthalmologists who may be
encouraged or even pressured to prescribe off-label bevaci-
zumab by their employing institutions or insurance compa-
nies. In such situations, it is even more important that the
patient is fully informed.
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